Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares Core MSCI EAFE ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $285.17 (market cap $39.89B), while iShares Core MSCI EAFE ETF trades at $96.71. The key difference: iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | IEFA | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $98.56 |
52-Week Low | $278.09 | $81.70 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
IEFA trades at $97.22, up 0.51% with a bullish technical signal from moving averages. The ETF provides developed international equity exposure excluding North America, offering diversification from US market concentration risks. Recent news highlights its competitive 0.07% expense ratio and 3.30% dividend yield compared to peers. Technical indicators show neutral oscillators but strong bullish momentum from moving averages.
The outlook remains positive given international diversification benefits and potential Fed rate cut catalysts. Key risks include currency fluctuations and developed market central bank policy shifts. With strong institutional interest and favorable analyst comparisons to broader international ETFs, IEFA presents a cost-effective developed markets exposure opportunity for US investors seeking geographic diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →
